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Abstract  Heart  failure  (HF)  is  a  major  health  problem  with  a  significant  impact  on  morbidity,
mortality,  quality  of  life  and  healthcare  costs.  Despite  the  positive  impact  of  disease-modifying
therapies  developed  over  the  last  four  decades,  HF  mortality  and  hospitalization  remain  high.
We aim  at  reviewing  the  evidence  supporting  the  use  of  sodium-glucose  co-transporter-2
(SGLT-2) inhibitors,  as  a  novel  strategy  for  HF  with  reduced  ejection  fraction  (HFrEF)  treatment.
The consistent  observation  of  a  reduction  in  HF  hospitalizations  in  type-2  diabetes  cardio-
vascular safety  trials  EMPA-REG  OUTCOME,  CANVAS,  DECLARE-TIMI  58  and  VERTIS  raised  the
hypothesis  that  SGLT-2  inhibitors  could  have  an  impact  in  HF  treatment.
This hypothesis  was  first  confirmed  in  2019  with  the  DAPA-HF  publication  showing  that
dapagliflozin  on  top  of  optimized  HFrEF  therapy,  reduced  HF-hospitalizations  and  cardiovas-
cular mortality.  This  was  reinforced  by  the  EMPEROR-Reduced  publication  in  2020  showing  that
empagliflozin  on  top  of  optimized  HFrEF  therapy,  reduced  HF-hospitalizations.  Both  studies
established  SGLT-2  inhibitors  as  a  fourth  pillar  of  HFrEF  prognosis-modifying  therapy,  in  addition
to the  gold  standard  triple  neurohormonal  modulation/blockade.sa  de  Cardiologia.  Published  by  Elsevier  España,  S.L.U.  This  is  an
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Inibidores  do  SGLT-2:  um  passo  em  frente  no  tratamento  da  ICFEr
Resumo  A  insuficiência  cardíaca  (IC)  é  um  importante  problema  de  saúde,  com  impacto  sig-
nificativo na  comorbidade,  mortalidade,  qualidade  de  vida  e  nos  custos  com  saúde.  Apesar  do
impacto positivo  das  terapias  modificadoras  de  prognóstico  desenvolvidas  nas  últimas  quatro
décadas, a  mortalidade  e  as  hospitalizações  por  IC  permanecem  elevadas.  O  nosso  objetivo  é
rever a  evidência  que  apoia  o  uso  de  inibidores  do  cotransportador  sódio-glicose  (inibidores
do SGLT-2)  como  uma  nova  estratégia  para  o  tratamento  de  IC  com  fração  de  ejeção  reduzida
(ICFEr). A  observação  consistente  de  uma  redução  nas  hospitalizações  por  IC  nos  ensaios  de
segurança cardiovascular  de  diabetes  tipo-2  EMPA-REG  OUTCOME,  CANVAS,  DECLARE-TIMI  58  e
VERTIS levantou  a  hipótese  de  que  os  inibidores  do  SGLT-2  poderiam  ter  um  impacto  no  trata-
mento da  IC.  Esta  hipótese  foi  confirmada  pela  primeira  vez  em  2019  com  a  publicação  do
DAPA-HF,  mostrando  que  a  dapagliflozina  adicionada  à  terapia  optimizada  para  ICFEr  reduziu
as hospitalizações  por  IC  e  a  mortalidade  cardiovascular.  Isso  foi  reforçado  pela  publicação  do
EMPEROR-Reduced  em  2020,  mostrando  que  a  empagliflozina,  adicionada  à  terapia  optimizada
para ICFEr  reduziu  as  hospitalizações  por  IC.  Ambos  os  estudos  estabeleceram  os  inibidores  do
SGLT-2 como  o  quarto  pilar  da  terapia  modificadora  do  prognóstico  da  ICFEr,  adicionada  ao  gold
standard do  tratamento  da  ICFEr  --  a  estratégia  de  modulação/bloqueio  neuro-hormonal  triplo.
© 2021  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.U.  Este é  um


























































eart  Failure  (HF)  is  a  deadly  condition.  During  the  1980s,
ve  years  after  first  onset  of  HF  symptoms,  around  75%  of  HF
atients  would  be  dead.  In  the  four  decades  that  followed,
here  was  significant  progress  in  HF  treatment,  resulting  in
he  emergence  of  a  series  of  disease-modifying  therapies
ith  a  positive  prognostic  impact  in  HF  with  reduced  ejec-
ion  fraction  (HFrEF).  Despite  this,  mortality  is  still  high  at
pproximately  50%  5  years  after  onset  of  first  HF  symptoms.
Heart  failure  with  reduced  ejection  fraction  prognosis-
odifying  pharmacological  therapy  is  currently  based
n  the  triple  combination  of  angiotensin-converting
nzyme  inhibitors  (ACEi)/angiotensin-II  receptor  blockers
ARB)/angiotensin  receptor-neprilysin  inhibitor  (ARNi),  with
 beta-blocker  (BB),  and  a  mineralocorticoid  receptor  antag-
nist  (MRA).1
In  2015,  the  EMPA-REG  OUTCOME  trial  publication2 raised
he  hypothesis  that  a  new  class  of  anti-diabetic  drugs  --
odium-glucose  co-transporter  2  (SGLT-2)  inhibitors  --  could
ave  an  impact  on  HF  treatment.  This  hypothesis  was  proven
orrect  in  2019,  with  the  publication  of  DAPA-HF.3 The  lat-
er  established  dapagliflozin  as  a  new  additional  step  in
he  aforementioned  triple  prognostic-modifying  therapy,  by
nducing  incremental  gains  in  HFrEF  prognosis.  This  was  rein-
orced  by  the  publication  in  2020  of  the  EMPEROR-Reduced4
tudy,  which  showed  identical  results  with  empagliflozin.
This  paper  aims  at  reviewing  the  evidence  that  supports
he  use  of  SGLT-2  inhibitors  as  a  fourth  pillar  of  contempo-
ary  HFrEF  treatment.. Sodium-glucose  co-transporter-2  inhibitors:  From  anti-





SGLT-2  inhibitors  were  initially  developed  for  the  treat-
ent  of  type  2  diabetes  (T2D).5 SGLT-2  inhibitors  currently
pproved  in  the  European  Union  include  dapagliflozin,
anagliflozin,  empagliflozin  and  ertugliflozin.
Sodium-glucose  co-transporter-2  inhibitors  are  responsi-
le  for  the  reabsorption  of  80-90%  of  the  glucose  filtered
y  the  glomeruli,  through  the  coupling  of  the  electrochem-
cal  energy  produced  by  active  sodium  transport  to  the
o-transport  of  glucose1.  SGLT-2  inhibitors  act  by  selective
nhibition  of  SGLT-2  at  the  proximal  tubule  of  the  nephron,
hus  improving  glycemic  control  by  blocking  glucose  reab-
orption  and  promoting  glucosuria.6 SGLT-2  inhibitors  were
ffective  at  lowering  glycated  hemoglobin,  as  well  as  redu-
ing  bodyweight  in  a  broad  spectrum  of  T2D  patients.5
In  recent  years,  several  cardiovascular  outcome  trials
ave  been  conducted  to  demonstrate  the  cardiovascular
afety  profile  of  SGTL-2  inhibitors  in  high  or  very-high  cardio-
ascular  risk  T2D  patients.  In  the  EMPA-REG  OUTCOME  trial,
mpagliflozin  compared  to  placebo,  was  shown  to  reduce
he  composite  primary  endpoint  of  death  due  to  cardio-
ascular  causes,  non-fatal  myocardial  infarction  or  nonfatal
troke  (3-point  major  cardiovascular  events  (MACE)).2 Simi-
ar  results  were  observed  in  the  CANVAS  program,7 in  which
anagliflozin  was  compared  to  placebo.  In  the  DECLARE-TIMI
8  trial,  dapagliflozin  compared  to  placebo  met  the  pre-
pecified  criterion  for  non-inferiority  with  respect  to  3-point
ACE,  and  the  same  was  observed  in  the  VERTIS  CV  study,8
n  which  ertugliflozin  was  compared  to  placebo.
Somewhat  unexpectedly,  in  all  four  of  the  abovemen-
ioned  studies,  a  reduction  in  HF  hospitalizations  was
bserved  in  the  drug-study  arm  as  compared  with  the  control
rm.2,7--9 Additionally,  in  the  EMPA-REG,  the  CANVAS  and  the
ECLARE-TIMI  58  trials,  a  reduction  in  the  composite  end-
oint  of  cardiovascular  death/HF  hospitalizations  was  also
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rm.2,7,9 This  raised  the  possibility  that  SGLT-2  inhibitors
ould  have  a  beneficial  effect  in  the  treatment  of  HF.10,11
.  Randomized  clinical  trials  of  SGLT-2  inhibitors  in  HF.
Consequently,  further  SGLT-2  inhibitors  studies  were  con-
ucted  among  patients  with  HF,  with  or  without  T2D,  under
ptimized  HF-therapy,  to  test  the  possible  additional  posi-
ive  effects  of  SGLT-2  inhibitors,  as  well  as  the  safety  of  this
trategy.  In  the  case  of  dapagliflozin,  these  were  the  DAPA-
F3 (in  patients  with  HfrEF)  and  the  ongoing  DELIVER12,13 (in
atients  with  HF  with  preserved  ejection  fraction  [HfpEF])
rials.  Similar  trials  were  conducted  with  empagliflozin  in
FrEF  and  HFpEF  patients:  the  EMPEROR-Reduced  and  the
ngoing  EMPEROR-Preserved  trials.4,14
DAPA-HF  was  an  international,  multicenter,  phase  3,
lacebo-controlled  trial  in  patients  with  chronic  HF,  with
r  without  T2D,  randomized  to  receive  dapagliflozin  10
g  or  placebo.3 The  study  included  patients  with  HFrEF
left  ventricular  ejection  fraction  [LVEF]≤40%),  New  York
eart  Association  (NYHA)  functional  class≥II,  elevated  N-
erminal  pro-B-type  natriuretic  peptide  (NT-proBNP)  and
nder  optimal  HF  therapy.3,15 The  latter  included  the  com-
ination  of  an  ACEi/ARB/sacubitril-valsartan  (Sac/Val),  plus
 BB,  and  a  MRA  unless  contraindicated  or  not  toler-
ted.  Additionally,  patients  were  permitted  an  implantable
ardioverter-defibrillator  (ICD),  or  cardiac  resynchroniza-
ion  therapy  (CRT),  or  both,  whenever  indicated.3,15
The  primary  outcome  was  the  composite  end-point  of
orsening  heart  failure  (WHF)  or  cardiovascular  death.  An
pisode  of  WHF  was  either  an  unplanned  hospitalization
ue  to  HF  or  an  urgent  visit  resulting  in  intravenous  HF
herapy.3,15
Overall  4744  patients  were  randomized:  94%  were  on  an
CEi,  or  an  ARB  or  on  Sac/Val;  96%  were  on  a  BB,  71%  on  MRA
nd  93%  on  diuretics.  A  sizable  proportion  of  patients  had  an
mplanted  device:  26%  had  an  ICD  and  8%  were  under  CRT.
2D  was  present  in  42%  of  patients.3 During  an  18.2-month
edian  follow-up,  the  primary  outcome  occurred  in  16.3%
f  patients  in  the  treatment  arm  vs.  21.2%  in  the  placebo
rm  (hazard  ratio  [HR]  0.74;  95%  confidence  interval  (CI),
.65-0.85;  p<0.001)  resulting  in  a  26%  WHF  risk  reduction
ith  dapagliflozin.3 The  difference  in  the  frequency  of  the
rimary  outcome  amongst  the  two  therapeutic  arms  reached
tatistical  significance  at  one  month  of  follow-up.3
A  first  WHF  event  occurred  in  10.0%  of  patients  on
apagliflozin  vs.  13.7%  on  placebo  (HR  0.70;  95%  CI,  0.59-
.83).3 Death  from  cardiovascular  causes  occurred  in  9.6%
atients  on  dapagliflozin  vs.  11.5%  patients  on  placebo  (HR
.82;  95%  CI,  0.69  to  0.98).  Results  of  the  primary  endpoint
ere  similar  amongst  patients  with  and  without  T2D.3
The  incidence  of  the  secondary  composite  outcome  of
ospitalization  for  HF  or  death  from  cardiovascular  causes
as  lower  in  the  dapagliflozin  group  than  in  the  placebo
roup  (HR  0.75,  95%  CI,  0.65-0.85;  p<0.001).3
Compared  to  the  placebo  group,  the  dapagliflozin  group
howed  a  higher  increase  in  the  Kansas  City  Cardiomyopathy
uestionnaire  Total  Symptom  Score  at  8  months  of  follow-up
s.  baseline  (HR  1.18,  95%  CI  1.11-1.26;  p<0.001).3 This  indi-
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ife  in  patients  with  HFrEF  already  under  optimal  background
rognosis-modifying  therapy.
Death  from  any  cause,  usually  interpreted  as  a  safety
ndpoint,  occurred  in  11.6%  patients  on  dapagliflozin  vs.
3.9%  patients  on  placebo  (HR  0.83,  95%  CI,  0.71  to  0.97).3
Finally,  in  the  dapagliflozin  group  compared  to  the
lacebo  group,  there  was  a  significant  decrease  in  NT-
roBNP  (p<0.001),  in  systolic  blood  pressure  (p=0.002),
n  glycated  hemoglobin  (p<0.001)  and  in  bodyweight
p<0.001),  whilst  a  significant  increase  in  hematocrit
p<0.001)  occurred.3
The  frequency  of  serious  adverse  events  and  specifically
hose  due  to  hypoglycemia,  hypovolemia  or  renal  insuffi-
iency  was  similar  amongst  treatment  groups.3
A  post-hoc  analysis  of  DAPA-HF  showed  that  the  impact
f  dapagliflozin  on  the  primary  outcome  was  consistent,
egardless  of  baseline  therapy,  including  the  presence  or
bsence  of  sacubitril/valsartan  (HR  for  the  primary  endpoint
f  0.75  (95%  CI,  0.50-1.13)  and  0.74  (95%  CI,  0.65-0.86),
espectively).16
Although  patients  enrolled  in  the  DAPA-HF  trial  were
nder  optimal  neuro-hormonal  blockade/modulation  (as
hown  by  the  high  rates  of  ACEis/ARBs/Sac-Val,  BBs  and
RAs)  before  randomization,  approximately  25%  of  those
andomized  to  placebo  had  a  primary  event  over  18  months,
ttesting  an  unmet  need  requiring  further  improvement  in
urrent  standard  therapy.3,15 DAPA-HF  showed  that  the  addi-
ion  of  dapagliflozin  to  current  optimal  medical  treatment
epresents  an  additional  step  towards  the  goal  of  saving
ives,  reducing  hospitalizations,  improving  symptoms  and
uality  of  life  in  patients  with  HFrEF,  regardless  of  the  pres-
nce  of  T2D.3,15,16 It  also  supported  the  EMA  approval  of
apagliflozin  as  a  HF  therapy  in  patients  without  T2D.
DAPA-HF  was  followed  by  the  DEFINE-HF  study  which
ncluded  263  HFrEF  (LVEF≤40%)  patients,  with  NYHA  func-
ional  class  II-III,  estimated  glomerular  filtration  (eGFR)  rate
30  mL/min/1.73  m2, and  elevated  natriuretic  peptides
nd  under  optimal  neuro-hormonal  blockade/modulation.17
atients  were  randomized  to  receive  dapagliflozin  10  mg  or
lacebo.  Compared  to  placebo,  dapagliflozin  did  not  show
 significant  improvement  in  NT-proBNP  neither  at  6  weeks
or  at  12  weeks  of  follow-up,  the  first  co-primary  outcome.17
he  second  dual  co-primary  outcome  of  a  ≥5  point  improve-
ent  in  KCCQ-Overall  Summary  Score  (KCCQ-OSS)  or  a  ≥20%
eduction  in  NT-proBNP  was  met  in  61.5%  of  dapagliflozin-
reated  patients  vs,  50.4%  in  placebo  group  (adjusted  odds
atio  [OR]  1.8,  95%  CI  1.03-3.06,  nominal  p=0.039).  This  was
ttributable  to  both  higher  proportions  of  patients  with  ≥5-
oint  improvement  in  KCCQ-OSS  (42.9  vs.  32.5%,  adjusted
R  1.73,  95%  CI  0.98-3.05),  and  ≥20%  reduction  in  NT-
roBNP  (44.0  vs.  29.4%,  adjusted  OR  1.9,  95%  CI  1.1-3.3)  by
2  weeks.  Results  were  consistent  among  patients  with  or
ithout  T2D,  and  other  pre-specified  subgroups  (all  p  values
or  interaction=non-significant).17
More  recently,  the  EMPEROR-Reduced  study  with
mpagliflozin  in  patients  with  HFrEF  was  published.18 This
as  a  phase  3,  placebo-controlled  study  (NCT03057977),
hich  involved  3,730  patients  with  NYHA  class  II-IV,  HF
ith  ejection  fraction  ≤40%  randomized  to  placebo  or
mpagliflozin  10  mg  daily,  added  to  guideline-directed
edical  therapy  (ACE  inhibitors/ARBs/ARNIs,  beta-blockers
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emographics  were  relatively  similar  to  the  DAPA-HF.4 The
rimary  endpoint  was  a  time-to-first-event  analysis  of  the
ombined  risk  of  HF  hospitalizations  or  CV  death.  After  a
edian  of  16  months,  the  primary  outcome  occurred  in  361
f  1863  patients  (19.4%)  in  the  empagliflozin  group  and  in
62  of  1867  patients  (24.7%)  in  the  placebo  group  (HR  0.75;
5%  CI  [0.65-0.86];  p<0.00).  This  was  primarily  driven  by
educed  rates  of  HF  hospitalization  in  the  empagliflozin
roup  (HR  0.70;  95%  CI  [0.58-0.85];  p<0.001).  The  trial
ailed  to  demonstrate  a  significant  reduction  in  CV  death
HR  0.92;  95%  CI  [0.75-1.12])  and  in  all-cause  mortality
HR  0.92;  95%  CI  [0.77-1.10])  compared  to  placebo.4 No
ifference  in  quality  of  life  as  measured  using  KCCQ  was
bserved  when  comparing  both  therapeutic  arms.  A  signif-
cant  reduction  was  observed  in  the  rate  of  renal  disease
rogression,  as  measured  by  eGFR  rate  slope  over  time,
n  the  empagliflozin  group  compared  to  patients  receiving
lacebo.4
The  adverse  events  profile  for  empagliflozin  was  similar
o  that  reported  in  previous  studies.4
In  summary,  the  results  of  DAPA-HF  and  EMPEROR-
educed  trials  consolidate  a  new  approach  to  HFrEF
anagement,  through  the  addition  of  SGLT-2  inhibitors
o  current  standard  triple  disease-modifying  therapy  in
atients  with  and  without  T2D.  These  studies  showed  that
apagliflozin  and  empagliflozin  are  effective  in  reducing
F  hospitalizations.  DAPA-HF  showed  that  dapagliflozin  can
educe  CV  death  in  patients  with  HFrEF.3,4,19
.  The  SOLOIST  WHF:  A  SGTL-2  and  SGLT1  inhibitor  random-
ized  trial  in  patients  with  type  2  diabetes  and  recent
worsening  heart  failure
The  recently  published  SOLOIST  WHF  in  patients  with  T2D
nd  recent  worsening  HF  showed  that  sotagliflozin  --  a  SGTL-
 and  SGLT1  inhibitor  --  versus  placebo,  initiated  before  or
hortly  after  discharge,  reduced  cardiovascular  mortality,
ospitalizations  and  urgent  visits  for  HF.20
.  Possible  mechanisms  explaining  the  benefits  of  SGLT-2
inhibitors
)  Remodeling
The  mechanisms  underlying  SGLT-2  inhibitors  benefits  in
ardiovascular  and  renal  events  remain  unclear.10,21
Left  ventricular  (LV)  remodeling  is  a  major  predictor  of
V  events  and  prognosis  in  HF,  therefore  the  effects  of  SGLT-
 inhibitors  in  remodeling21 may,  at  least  in  part,  explain  the
enefits  observed  in  HF.22
Many  different  additional  hypotheses  have  been  put  for-
ard,  such  as  the  effect  of  SGLT-2  inhibitors  on  promoting
iuresis/natriures,10,11,23--25 on  improving  cardiometabolic
fficiency,22,26,27 blood  pressure  profile  and  renal  func-
ion.  Other  explanatory  hypotheses  include  the  increase  in
emoglobin  concentration  among  others.
)  The  ‘‘smart  diuretic’’  hypothesisBy  inducing  SGLT-2  inhibition  at  the  proximal  tubule,
GLT-2  inhibitors  promote  glycosuria  and  natriuresis.  This,
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esulting  in  a  decrease  in  LV  end-diastolic  pressure  (LVEDP)
nd  congestion.  The  latter  is  responsible  for  90%  of  HF
ospitalizations.22 This  decrease  in  LVEDP  may  lead  to  dimin-
shed  cardiomyocyte  cytosqueletal  stimulation,  which  is  a
ajor  LV  remodeling  pathway,  and  consequently  a  determi-
ant  of  bad  prognosis  in  HF.10
Moreover,  additional  sodium-hydrogen  exchanger  3  chan-
el  inhibition  at  the  proximal  tubule  further  contributes  to
ncreased  diuresis  and  natriuresis,  decreased  intravascular
olume,  increased  hemoconcentration,  and  reduced  body
eight  and  blood  pressure.  All  of  these  effects  may  lead
o  a  reduction  in  LV  wall  stress  which,  in  turn,  may  also
ead  to  diminished  deleterious  cytoskeletal  pro-proliferative
ignaling  and  consecutive  LV  remodeling.10
Sodium-glucose  co-transporter-2  inhibitors  may  selec-
ively  reduce  interstitial  volume  with  minimal  change  in
ntra-vascular  volume.28,29 This  enables  the  reduction  of
ongestion  without  decreasing  afferent  arteriole  pressure,
hus  not  activating  the  sympathetic  nervous  system  (SNS)
rive.28--32
As  opposed  to  conventional  diuretics,  which  can  reduce
V  end-diastolic  pressure  at  the  cost  of  harmful  SNS  activa-
ion,  SGLT-2  inhibitors  can  reduce  cytoskeletal  stimulation
ith  no  neurohormonal  activation.10 SGLT-2  inhibitors  also
ttenuate  STAT3  phosphorylation,  leading  to  decreased
yocardial  extracellular  matrix  accumulation  and  cardiac
brosis.10
Thus,  preliminary  evidence  seems  to  suggest  that  the
eneficial  effects  of  SGLT-2  inhibitors  in  HF  may  involve
V  remodeling  attenuation10,28,29 via  a  diuretic-like  effect,
lthough  without  the  neuro-hormonal  activation  associated
ith  conventional  diuretics.
) The  cardio-renal  hypothesis
Heart  failure  hospitalizations  are  due  to  congestion  in
0%  of  the  cases.  SGLT-2  inhibitors  reduce  the  rate  of  decline
n  renal  function  among  diabetic  patients.33 This  could  be
elevant  in  decreasing  HF  hospitalizations.
)  The  cardiometabolic  efficiency  hypothesis
By  lowering  blood  pressure,  increasing  aortic  compli-
nce  and  improving  ventricular-arterial  coupling,  SGLT-2
nhibitors  can  reduce  cardiac  workload  and  myocar-
ial  oxygen  consumption.10 These  benefits  can  be
mplified  by  hemoconcentration,  leading  to  increased
emoglobin/oxygen-carrying  capacity.10,25
A  change  in  cardiac  fuel  supply  by  shifting  glucose  oxi-
ation  to  a more  efficient  fat/ketones  oxidation  has  been
ypothesized  by  some  authors.28
Finally,  by  inhibiting  sodium/hydrogen  exchanger-1  in
ardiomyocytes,  SGLT-2  inhibitors  improve  mitochondrial
unction  in  cardiomyocytes,  which  is  crucial  for  cardiomy-
cyte  function  and  survival.29
Several  studies  investigating  the  impact  of  SGLT-2
nhibitors  are  currently  ongoing  or  have  recently  been  com-
leted,  including  mechanistic  studies  of  empagliflozin  and
apagliflozin.29,31 Results  of  this  research  will  provide  more
nformation  and  details  about  the  potential  mechanisms  of
ction  of  SGLT-2  inhibitors  and  implications  for  cardiovascu-
ar  benefits.
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Table  1  Expert  consensus  on  the  use  of  dapagliflozin  in  heart  failure  patients  with  reduced  ejection  fraction,  according  to
DAPA-HF results  and  the  regulatory  agency’s  approval.
Question  Experts’  perspective
What  is  the  target  HF  population  for
dapagliflozin?
Based  on  current  evidence  the  appropriate  target
population  is  patients  with  HFrEF  (NYHA≥II)  with  or
without  diabetes,  in  the  absence  of
eGFR<30mL/min/1.73  m2,  hypotension  or  T1D.
Important  comorbidities  to  consider  when  initiating
dapagliflozin  are  chronic  kidney  disease,  liver
disease,  vascular  disease  and  cancer.
At which  point  of  the  HFrEF  therapeutic
algorithm  should  dapagliflozin  be  introduced?
Dapagliflozin  should  be  used  in  addition  to  RAAS
inhibitors,  plus  BB  or  devices  (when  indicated).  The
initiation  of  dapagliflozin  should  be:
Concomitant  to  NH  blockade/modulation  therapy
titration  in  patients  with  HFrEF  and  diabetes
After  titration  of  NH  blockade/modulation  therapy
in patients  with  HFrEF  and  no  diabetes.
What should  be  discussed  with  the  patient
when  considering  the  initiation  of
dapagliflozin?
•  The  costs  (how  to  handle  the  costs  of
polypharmacy)
• Side  effects  (the  prevention  of  genital  infection)
• The  importance  of  hydration
•  What  to  do  in  case  of  fever  or  acute  illness,
keto-acidosis  symptoms  (frequent  urination,
excessive  thirst,  shortness  of  breath,  nausea  and
vomiting,  abdominal  pain,  weakness  or  fatigue,
somnolence  or  confusion)
•  And  strict  maintenance  of  NH  blockers/modulators.
What gaps  in  evidence  still  remain  regarding
the use  of  dapagliflozin  in  HF?
•  What  are  the  mechanisms  of  action?
• Is  there  a  class  effect  or  are  there  differences
between  the  different  SGLT2i?
• When  should  dapagliflozin  be  added  to  HF  therapy?
• Should  dapagliflozin  be  maintained/added  during
HF decompensation  (acute  HF)?
• Do  dapagliflozin  benefits  extend  to  HFpEF/HFmrEF
with  or  without  T2D?
•  Can  dapagliflozin  be  used  in  T1D?
BB: beta-blocker; T1D: type 1 diabetes; T2D: type 2 diabetes; eGFR: estimated glomerular filtration rate; HF: heart failure; HFpEF:































Heart Association; RAAS inhibitors: include angiotensin-convertin
sacubitril--valsartan (Sac/Val) and mineralocorticoid receptor ant
.  Implications  for  clinical  practice
The  impact  of  the  abovementioned  SGLT-2  inhibitor  tri-
ls  in  patients  with  HFrEF  in  the  soon-to-be  published
021  European  Society  of  Cardiology  Heart  Failure  guide-
ines  remains  unknown.  However,  the  unmet  need  for  new
isease-modifying  therapies  that  may  further  improve  sur-
ival,  morbidity,  functional  capacity  and  quality  of  life  in
F,  as  has  already  been  demonstrated  with  SGLT  inhibitors,
s  well  recognized.  As  a  consequence,  dapagliflozin  recently
ecame  the  first  SGLT-2  inhibitor  to  be  approved  by  the
uropean  Medicines  Agency  for  the  treatment  of  HFrEF
atients.  In  order  to  incorporate  this  into  clinical  prac-
ice,  Table  1  summarizes  the  experts’  consensus  on  the  use
f  dapagliflozin  in  the  treatment  of  patients  with  HFrEF,






zyme inhibitors (ACEis), angiotensin II-receptor blockers (ARBs),
sts (MRAs); SGLT2i: sodium-glucose cotransporter-2 inhibitors.
onclusions
eart  failure  is  a  highly  prevalent  syndrome  and  is  associated
ith  high  morbidity,  mortality  and  costs.  Both  the  DAPA-HF
nd  the  EMPEROR-Reduced  studies  showed  that,  in  addi-
ion  to  optimized  contemporary  HFrEF  therapy,  dapagliflozin
nd  empagliflozin  were  effective  in  reducing  HF  hospital-
zations.  Moreover,  dapagliflozin  demonstrated  a  significant
eduction  in  CV  death.  In  both  studies  the  results  were
bserved  independently  of  the  presence  of  T2D.  The  mech-
nisms  explaining  these  results  are  not  entirely  clear  and
o  beyond  controlling  blood  glucose.  They  may  include
he  contribution  of  congestion  control,  the  improvement  in
ardio-metabolic  efficiency  and  the  reduction  in  ventricular
emodeling,  among  others.
DAPA-HF  and  EMPEROR-Reduced  trials  provided  evidence
or  the  addition  of  dapagliflozin  or  empagliflozin  to  the
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trategy  in  patients  with  HFrEF.  Thus,  SGLT-2  inhibitors
ave  emerged  as  the  fourth  pillar  of  the  pharmacological
isease-modifying  therapy  in  HFrEF  patients,  regardless  of
he  presence  or  absence  of  T2D.
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